---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000035"
form_type: "8-K"
ticker: null
cik: "0001733294"
company_name: "Generation Bio Co."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T11:08:51.401353+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Generation Bio pivots to ctLNP siRNA for autoimmune diseases; CFO, CSO exit; cuts 20% staff

## Summary
- New focus on ctLNP-delivered siRNA for T cell-driven autoimmune diseases; first IND expected 2H 2026.
- CFO Matthew Norkunas departs Jan 10; Kevin Conway appointed CFO with $420K salary and 290,960 option grant.
- CSO Matthew Stanton departs; Phillip Samayoa appointed CSO with $510K salary; Stanton to consult through mid-2025.
- Workforce reduced ~20%; severance costs estimated $1-2M; cash runway into 2H 2027.

## SEC filing metadata
- accession: 0001558370-25-000035
- form_type: 8-K
- cik: 0001733294
- company_name: Generation Bio Co.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733294/000155837025000035/0001558370-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733294/000155837025000035/gbio-20250106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000035
- JSON: https://secwatch.observer/filing/0001558370-25-000035.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000035.txt

## Key facts
- Executive change
  Matthew Norkunas departed as Chief Financial Officer at Generation Bio Co..
  - Action: departure
  - Role: Chief Financial Officer
  source text: On January 6, 2025, Generation Bio Co. (the “Company”) and Matthew Norkunas, MD, MBA agreed that they will enter into a separation agreement (the “Norkunas Separation Agreement”) for Dr. Norkunas’s departure as the Company’s Chief Financial Officer, effective as of January 10, 2025 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733294/000155837025000035/0001558370-25-000035-index.htm
- Executive change
  Matthew Stanton departed as Chief Scientific Officer at Generation Bio Co..
  - Action: departure
  - Role: Chief Scientific Officer
  source text: On January 6, 2025, the Company and Matthew Stanton, Ph.D. agreed that they will enter into a separation agreement (the “Stanton Separation Agreement”) for Dr. Stanton’s departure as the Company’s Chief Scientific Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733294/000155837025000035/0001558370-25-000035-index.htm
- Executive change
  Kevin Conway was elected as Chief Financial Officer at Generation Bio Co..
  - Action: elected
  - Role: Chief Financial Officer
  source text: On January 6, 2025, the Board of Directors (the “Board”) of the Company elected Kevin Conway to serve as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733294/000155837025000035/0001558370-25-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.